A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis

NCT00379600 Phase 2 COMPLETED

To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	COMPLETED
Enrolment	96
Start date	2004-11
Completion	2006-12

Conditions

• Arthritis, Rheumatoid

Interventions

• rosiglitazone XR

Primary outcomes

• Disease Activity Score (DAS) following 6 months of treatment — 6 Months

Countries

Lithuania, United Kingdom